Rini, Brian <br/><br/>
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.  [electronic resource] 

 -  Cancer  Dec 2012 
 - 6152-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.27632  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Benzenesulfonates--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Carcinoma, Renal Cell--drug therapy<br/>Double-Blind Method<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Prognosis<br/>Pyridines--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Sorafenib<br/>Survival Rate